Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

NCT03779113 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT03779113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03779113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Lead sponsor
Hutchmed
Phase
Phase 1
Overall status
Terminated
Start date
September 26, 2019
Completion date
February 26, 2025
Enrollment
69 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma